ERBB2 and neoplasm: One approach involves fusion proteins that link melittin to targeting ligands such as gelonin, VEGF165, or disintegrin, which can bind to tumor-specific receptors including HER2 and receptors expressed in triple-negative breast cancer (TNBC) [18,60,61,62].